CD19-Targeted T Cells Rapidly Induce Remissions in Leukemia Patients

Renier Brentjens of Memorial Sloan-Kettering on cell therapy and leukemiaRenier Brentjens, Medical Oncologist at Memorial Sloan-Kettering Cancer Center, co-authored this interesting paper, ‘CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia,' originally published in Science Translational Medicine Vol. 5, Issue 177.

View the full article here, with permission by Science Translational Medicine.


"Adults with relapsed B cell acute lymphoblastic leukemia (B-ALL) have a dismal prognosis. Only those patients able to achieve a second remission with no minimal residual disease (MRD) have a hope for long-term survival in the context of a subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT). We have treated five relapsed B-ALL subjects with autologous T cells expressing a CD19-specific CD28/CD3ζ second-generation dual-signaling chimeric antigen receptor (CAR) termed 19-28z. All patients with persistent morphological disease or MRD+ disease upon T cell infusion demonstrated rapid tumor eradication and achieved MRD− complete remissions as assessed by deep sequencing polymerase chain reaction. Therapy was well tolerated, although significant cytokine elevations, specifically observed in those patients with morphologic evidence of disease at the time of treatment, required lymphotoxic steroid therapy to ameliorate cytokine-mediated toxicities. Indeed, cytokine elevations directly correlated to tumor burden at the time of CAR-modified T cell infusions. Tumor cells from one patient with relapsed disease after CAR-modified T cell therapy, who was ineligible for additional allo-HSCT or T cell therapy, exhibited persistent expression of CD19 and sensitivity to autologous 19-28z T cell-mediated cytotoxicity, which suggests potential clinical benefit of additional CAR-modified T cell infusions. These results demonstrate the marked antitumor efficacy of 19-28z CAR-modified T cells in patients with relapsed/refractory B-ALL and the reliability of this therapy to induce profound molecular remissions, forming a highly effective bridge to potentially curative therapy with subsequent allo-HSCT."

Check out the full article here.

Dr. Brentjens will be speaking at the upcoming Stem Cells & Regenerative Medicine Congress, taking place in Cambridge, MA on September 30 – October 1.

He will be speaking on the topic:

Deploying small studies to uncover new therapy pathways:

  • A closer look into new findings on T-cells potential to combat cancer
  • How will these studies spur interest in gene therapies and back up funding for new trials
  • Developing ways of overcoming potential T-cells limitations in anticipation to clinical trials
  • Strengthening phase II data to ensure NDA approval

Book now to hear him share his insights on this topic, or download the brochure for more information.

Leave a Reply

Your email address will not be published. Required fields are marked *